Colorectal Cancer

>

Latest News

FDA Grants Multiple Breakthrough Therapy Designations to Trastuzumab Deruxtecan
FDA Grants Multiple Breakthrough Therapy Designations to Trastuzumab Deruxtecan

August 31st 2023

Fam-trastuzumab deruxtecan-nxki was granted 2 breakthrough therapy designations by the FDA for its potential to fill a treatment gap for HER2-expressing tumors.

ME-344 Plus Bevacizumab Therapy Begins in Patients With Previously-Treated mCRC
ME-344 Plus Bevacizumab Therapy Begins in Patients With Previously-Treated mCRC

August 28th 2023

FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in mCRC
FDA Approves Trifluridine/Tipiracil Plus Bevacizumab in mCRC

August 2nd 2023

Part B of the DeFianCe Study Initiates Enrollment of Patients With CRC
Part B of the DeFianCe Study Initiates Enrollment of Patients With CRC

July 14th 2023

Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC
Botensilimab/Balstilimab Yields Durable Responses in Non-MSI-H mCRC

July 6th 2023

Video Series
Video Interviews
Podcasts

More News